Matched GMP and RUO Human iPSC Lines

Watch this webinar to learn how LineaBio’s GMP manufacturing framework, combined with STEMCELL’s rigorous quality control for matched RUO cell lines, can support your hiPSC-derived cell therapy development. You may also sign up to be notified when these products launch. Presented at ISSCR 2026; this presentation does not represent an endorsement from or support of the ISSCR.

Reliable and traceable starting materials, such as high-quality human induced pluripotent stem cell (hiPSC) lines, are essential for enabling reproducible hiPSC-derived cell therapy development. However, many research-grade materials are generated under donor, consent, or process constraints that prevent rederivation under GMP conditions, which limits their suitability for clinical translation.

To address these challenges, LineaBio has introduced the GMP hiPSC lines, Linea 1 and Linea 2, produced under defined, quality-controlled processes. In partnership with STEMCELL Technologies, matched RUO equivalents are derived from the same source material and qualified to meet or exceed ISSCR standards. Selecting matched starting materials enables smoother advancement through therapy development stages and lowers the likelihood of requiring process redesign at later phases.

Watch this webinar to learn how LineaBio’s GMP manufacturing framework, combined with STEMCELL’s rigorous quality control for matched RUO cell lines, can support your hiPSC-derived cell therapy development. You may also sign up to be notified when these products launch.

As a supporter of, and participant in, ISSCR’s 2026 Annual Meeting, we share with you our presentation at ISSCR 2026. This presentation does not represent an endorsement from or support of the ISSCR.
Publish Date: January 28, 2026